Denovo Biopharma LLC, of San Diego, entered a global license agreement with Stanford University School of Medicine. The deal allows Denovo to develop and commercialize DB-102 (enzastaurin), its lead compound, to treat pulmonary arterial hypertension (PAH) and emphysema.